CBM NX
Alternative Names: CBM-NXLatest Information Update: 28 Feb 2025
At a glance
- Originator CellionBioMed
- Class Anti-inflammatories; Antihypertensives; Antineoplastics; Antipsoriatics; Antirheumatics
- Mechanism of Action Small-conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
- Phase I Pulmonary hypertension
- No development reported Psoriasis; Rheumatic disorders; Systemic lupus erythematosus
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Psoriasis in South Korea
- 28 Feb 2025 No recent reports of development identified for phase-I development in Rheumatic-disorders in South Korea
- 28 Feb 2025 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in South Korea